References
- LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 1990: 81(5): 1721–33
- The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988: 148(1): 36–69
- Bays HE, Dujovne CA. Cardiovascular risk reduction and hormonal therapy in women. Infect Dis J Obstet Gynecol (in press)
- Dujovne CA, Harris WS. The pharmacological treatment of dyslipidemia. Annu Rev Pharmacol Toxicol 1989: 29: 265–88
- Vega GL, Grundy SM. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA 1989: 262(22): 3148–53
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984: 251(3): 351–64
- The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984: 251(3): 365–74
- Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984: 69(2): 313–24
- Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987: 257(23): 3233–40 [erratum, JAMA 1988; 259(18): 2698]
- Cashin-Hemphill L, Sanmarco ME, Blankenhorn DH. Augmented beneficial effects of colestipol-niacin therapy at four years in the C.L.A.S. trial. (Abstr) Circulation 1989: 80(Suppl II): 381
- Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990: 323(19): 1289–98
- Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990: 264(23): 3007–12
- East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988: 109(1): 25–32
- Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986: 8(6): 1245–55
- MBewu AD, Durrington PN. Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990: 85(1): 1–14
- Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA 1990: 264(2): 241–3
- Hodis HN. Acute hepatic failure associated with the use of low-dose sustained-release niacin. (Letter) JAMA 1990: 264(2): 181
- Dujovne CA, Chremos AN, Pool JL, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991: 91(1B): 25–30S
- Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991: 151(1): 43–9
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J 1978: 40(10): 1069–118
- Lavie CJ, O'Keefe JH, Blonde L, et al. High-density lipoprotein cholesterol: recommendations for routine testing and treatment. Postgrad Med 1990: 87(7): 36–51
- Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987: 317(20): 1237–45
- Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988: 260(5): 641–51
- Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment, Circulation 1992: 85: 37–45
- Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990: 264(23): 3025–33